Company Oncobiologics Inc Nasdaq
Equities
US68235M2044
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
Business Summary
Managers
Managers | Title | Age | Since |
---|---|---|---|
C. Trenary
CEO | Chief Executive Officer | 66 | 21-07-06 |
Lawrence Kenyon
DFI | Director of Finance/CFO | 58 | 15-09-14 |
Surendra Sharma
CTO | Chief Tech/Sci/R&D Officer | - | 23-01-18 |
Terry Dagnon
COO | Chief Operating Officer | 62 | 18-10-31 |
Alicia Tozier
SAM | Sales & Marketing | - | 22-03-01 |
Joel Prieve
PRN | Corporate Officer/Principal | - | 22-02-07 |
Jeff Evanson
PRN | Corporate Officer/Principal | 55 | 18-10-31 |
Jennifer Kissner
PRN | Corporate Officer/Principal | - | 19-04-25 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Randy Thurman
CHM | Chairman | 74 | 18-04-12 |
Kurt Hilzinger
BRD | Director/Board Member | 63 | 15-12-10 |
C. Trenary
CEO | Chief Executive Officer | 66 | 21-07-06 |
Lawrence Kenyon
DFI | Director of Finance/CFO | 58 | 15-09-14 |
Yazan Haddadin
BRD | Director/Board Member | 48 | 17-10-30 |
Julian Gangolli
BRD | Director/Board Member | 66 | 20-04-19 |
Gerd Auffarth
BRD | Director/Board Member | 59 | 20-04-19 |
Julia Haller
BRD | Director/Board Member | 69 | 22-08-10 |
Director/Board Member | 39 | 17-09-10 | |
Andong Huang
BRD | Director/Board Member | 27 | 20-06-18 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 23,405,637 | 14,743,307 ( 62.99 %) | 0 | 62.99 % |
Company contact information
Outlook Therapeutics, Inc.
111 South Wood Avenue Unit 100
08830, Iselin
+609 619 3990
http://www.outlooktherapeutics.comSector
1st Jan change | Capi. | |
---|---|---|
+34.14% | 51.12B | |
-6.54% | 39.4B | |
+34.92% | 38.48B | |
+12.62% | 26.36B | |
-12.11% | 26.22B | |
-13.43% | 20.96B | |
+43.73% | 14.02B | |
+31.81% | 12.49B | |
-4.54% | 11.61B |
- Stock Market
- Equities
- OTLK Stock
- Stock
- Company Oncobiologics Inc